Saturday 17 October 2026
Export PHAR’s income statement to Excel — free account
Pharming Group N.V. Sponsored ADR
PHAR Healthcare Biotechnology
Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024. In the quarter to June 2026, revenue fell 3.22%, EPS fell 57.1%, free cash flow fell 183.9% and total debt rose 1.55%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
9.36
0.27
−2.80%
Follow PHAR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
92.60 | 87.58 | 441.75 | 1,450.00 |
+8 more quarters Free account |
P/S ratio |
2.02 | 3.35 | 3.24 | 2.73 | |
P/FCF ratio |
21.56 | 22.24 | 22.56 | 18.76 | |
P/Operating CF |
(76.70) | 634.83 | 113.67 | 30.87 | |
P/B ratio |
2.74 | 4.61 | 4.39 | 3.74 | |
Price to Tangible BV |
5.20 | 8.98 | 8.60 | 7.62 | |
EV/Sales |
1.86 | 3.16 | 3.02 | 2.54 | |
EV/EBITDA |
22.26 | 29.38 | 30.63 | 21.93 | |
EV/Operating CF |
19.42 | 20.68 | 20.75 | 17.25 | |
EV/FCF |
19.80 | 20.95 | 21.04 | 17.46 | |
Quick Ratio |
2.31 | 2.06 | 2.03 | 2.39 | |
Current Ratio |
3.01 | 2.63 | 2.59 | 3.16 | |
Net Debt/EBITDA |
(13.93) | 40.19 | (8.62) | (3.70) | |
Debt/Assets |
20.91% | 20.18% | 19.61% | 20.76% | |
Debt/Equity |
0.36 | 0.37 | 0.35 | 0.37 | |
Asset Turnover |
0.80 | 0.83 | 0.84 | 0.81 | |
Operating CF/Net income |
(6.04) | (0.37) | 1.96 | 4.27 | |
Capex/Depreciation |
(0.03) | (0.08) | (0.08) | (0.03) | |
Research and Development Expense of Revenue |
35.81% | 35.28% | 30.15% | 24.05% | |
Selling, General and Administrative Expense of Revenue |
48.23% | 62.85% | 48.15% | 52.52% | |
Intangible Assets out of Total Assets |
0.27 | 0.27 | 0.27 | 0.28 | |
Share Based Compensation of Revenue |
3.71% | 4.45% | 4.23% | 3.29% | |
Graham Net Nets |
0.11 | 0.06 | 0.06 | 0.07 | |
Graham Number |
4.14 | 3.93 | 1.90 | 0.93 | |
Earnings Yield |
1.08% | 1.14% | 0.23% | 0.07% | |
Free Cash Flow Yield |
4.64% | 4.50% | 4.43% | 5.33% | |
Revenue per Share |
1.69 | 0.97 | 1.55 | 1.43 | |
Operating CF per Share |
(0.18) | 0.03 | 0.16 | 0.47 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.18) | 0.02 | 0.15 | 0.47 | |
Cash per Share |
2.97 | 2.29 | 2.61 | 2.45 | |
Shareholders Equity per Share |
5.07 | 3.61 | 4.02 | 3.88 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.07 | 3.61 | 4.02 | 3.88 | |
Free Cash Flow |
(9.74) | 1.71 | 10.44 | 31.96 | |
Working Capital |
187.44 | 183.17 | 183.68 | 189.69 | |
Capital Expenditures |
(0.08) | (0.24) | (0.27) | (0.07) | |
Net Current Asset Value |
83.20 | 75.11 | 76.61 | 68.46 | |
EV/EBIT |
36.83 | 41.72 | 43.93 | 35.06 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
40.10 | 44.30 | 47.10 | 37.67 | |
| Other line items | |||||
Average Receivables |
55.15 | 53.76 | 54.76 | 45.90 | |
Average Payables |
80.35 | 86.14 | 86.26 | 75.43 | |
Average Inventory |
64.57 | 61.96 | 60.31 | 64.68 | |
Average Assets |
457.12 | 446.27 | 449.97 | 449.65 | |
Average Common Equity |
255.02 | 242.13 | 249.08 | 245.22 |
Columns are period end dates